Last reviewed 2026-04-23 · How we verify

Injection of C3BS-CQR-1

C3BS-CQR-1 is an allogeneic CAR-T cell therapy engineered to target and kill cancer cells expressing specific tumor antigens.

C3BS-CQR-1 is an allogeneic CAR-T cell therapy engineered to target and kill cancer cells expressing specific tumor antigens. Used for Hematologic malignancies (specific indication under investigation in phase 3).

At a glance

Mechanism of action

C3BS-CQR-1 consists of genetically modified T cells derived from healthy donors that are equipped with chimeric antigen receptors (CARs) to recognize and eliminate cancer cells. The therapy is designed to be off-the-shelf, allowing for rapid administration without the need for patient-specific cell manufacturing. It represents an allogeneic approach to CAR-T cell immunotherapy, potentially offering broader accessibility compared to autologous CAR-T therapies.

Approved indications

• Hematologic malignancies (specific indication under investigation in phase 3)

Common side effects

• Cytokine release syndrome
• Immune effector cell-associated neurotoxicity syndrome (ICANS)
• Infections
• Cytopenias

Key clinical trials

• Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure. (PHASE3)
• Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Injection of C3BS-CQR-1 CI brief — competitive landscape report
• Injection of C3BS-CQR-1 updates RSS · CI watch RSS
• Celyad Oncology SA portfolio CI